NCT00050297终止2 期
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 试验地点
- 28
研究概览
简要总结
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (28)
Loading locations...
相似试验
已完成
2 期
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung CancerNon-Small-Cell Lung CancerNCT00363766Eli Lilly and Company52
已完成
2 期
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial FibrillationAtrial FibrillationNCT00938730Astellas Pharma Inc1,280
已完成
1 期
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00372853AstraZeneca28
已完成
1 期
A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly SubjectsHealthy Elderly SubjectPharmacokinetic of YM150NCT01514825Astellas Pharma Inc36
已完成
1 期
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid LeukemiaAcute Myeloid LeukemiaEssential ThrombocythemiaNCT00718159Eli Lilly and Company23